Aardvark Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced its participation in the 2025 United in Hope Conference in Phoenix, Arizona, from June 24 to 28. During the event, Aardvark will present previously disclosed data from its Phase 2 study of ARD-101 in Prader-Willi Syndrome $(PWS)$ through a poster and a five-minute "lightning" oral presentation. These presentations, titled "Reduction in Hyperphagia in the ARD-101 Phase 2 Clinical Trial Informs Phase 3 HERO Trial in PWS," will focus on ARD-101's favorable safety profile and early evidence of reduced hyperphagia. These findings have informed the design of the ongoing Phase 3 HERO study, which is currently enrolling patients with PWS. Additionally, Aardvark's Chief Medical Officer, Dr. Manasi Jaiman, will participate in a panel discussion on the Phase 3 HERO study. The company's team members will also engage with the medical community and families attending the conference to provide further information about ARD-101 and the HERO study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.